Schlag Anne Katrin, Lynskey Michael, Fayaz Alan, Athanasiou-Fragkouli Alkyoni, Brandner Brigitta, Haja Barbara, Iveson Elizabeth, Nutt David J
Drug Science, London, United Kingdom.
Department of Psychiatry, Imperial College London, London, United Kingdom.
Front Pain Res (Lausanne). 2022 Jun 14;3:891498. doi: 10.3389/fpain.2022.891498. eCollection 2022.
Prescribed cannabinoids are now legal in the UK and increasingly being used for a variety of conditions, with one of the most frequent conditions being chronic pain. This paper describes the characteristics of individuals seeking prescribed cannabinoids for the treatment of chronic pain in Project Twenty 21, a UK based real world data registry of prescribed cannabis patients.
By 1st November 2021 data were available for 1,782 people who had sought treatment with medical cannabis as part of Project Twenty 21. The most common diagnosis among this cohort was chronic pain with 949 (53.5%) of the cohort reporting a primary condition related to chronic pain. Medical and self-report data on the characteristics of these patients, their health status and type/s of cannabinoid/s prescribed are summarized in this report.
Of the 949 people reporting chronic pain as a primary condition 54.7% were male and their average age was 42.0 years (range = 18-84). Patients reported a low quality of life and high levels of comorbidity: people reported an average of 4.6 comorbid conditions with the most common comorbid conditions including anxiety, depression, insomnia and stress. A range of cannabinoid products were prescribed with the most common products being classified as high THC flower (48.5%). The majority of patients also reported using at least one other prescribed medication (68.7%).
Consistent with findings in other national and international databases, chronic pain was the most common primary condition in this real world study of prescribed cannabinoids. There was considerable variation in the types of chronic pain, comorbid pathology and in the characteristics of products being prescribed to treat these conditions. Together, this evidence supports the utility of real world evidence, as opposed to clinical trial approaches to studying the potential benefits of prescribed cannabinoids in treating chronic pain.
在英国，处方类大麻素现已合法化，并越来越多地用于各种病症，其中最常见的病症之一是慢性疼痛。本文描述了在“2021项目”中寻求处方类大麻素治疗慢性疼痛的个体特征，该项目是一个基于英国的处方大麻患者真实世界数据登记处。
截至2021年11月1日，有1782人作为“2021项目”的一部分寻求医用大麻治疗，相关数据可用。该队列中最常见的诊断是慢性疼痛，949人（占队列的53.5%）报告主要病症与慢性疼痛有关。本报告总结了这些患者的特征、健康状况以及所开处方大麻素的类型等医学和自我报告数据。
在949名报告慢性疼痛为主要病症的人中，54.7%为男性，平均年龄为42.0岁（范围为18 - 84岁）。患者报告生活质量较低且合并症水平较高：人们平均报告有4.6种合并症，最常见的合并症包括焦虑、抑郁、失眠和压力。开出了一系列大麻素产品，最常见的产品被归类为高四氢大麻酚含量的花（48.5%）。大多数患者还报告使用了至少一种其他处方药（68.7%）。
与其他国家和国际数据库的研究结果一致，在这项关于处方类大麻素的真实世界研究中，慢性疼痛是最常见的主要病症。在慢性疼痛的类型、合并病理以及用于治疗这些病症的产品特征方面存在相当大的差异。总体而言，这一证据支持了真实世界证据的实用性，与研究处方类大麻素治疗慢性疼痛潜在益处的临床试验方法形成对比。
